Polarityte Inc (PTE) |
|
1.38 0.02 (1.47%)
|
02-25 11:27 |
|
Open: |
1.37 |
Pre. Close: |
1.36 |
|
High:
|
1.4687 |
Low:
|
1.36 |
|
Volume:
|
2,305,755 |
Market Cap:
|
92M |
|
|
|
|
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.429 - 1.443 |
1.443 - 1.451 |
|
Low:
|
1.321 - 1.339 |
1.339 - 1.35 |
|
Close:
|
1.34 - 1.368 |
1.368 - 1.386 |
|
Technical analysis |
as of: 2021-02-25 11:16:02 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.84 One year: 2.32 |
| Support: |
Support1: 0.90 Support2: 0.75 |
| Resistance: |
Resistance1: 1.57 Resistance2: 1.99 |
| Pivot: |
1.50  |
| Moving Average: |
MA(5): 1.46  MA(20): 1.38
MA(100): 0.98 MA(250): 1.10 |
| MACD: |
MACD(12,26): 0.12 Signal(9): 0.15 |
| Stochastic oscillator: |
%K(14,3): 35.40 %D(3): 45.22 |
| RSI: |
RSI(14): 52.41 |
| 52-week: |
High: 2.38 Low: 0.55 Change(%): 1.1 |
| Average Vol(K): |
3-Month: 844598 10-Days: 710531 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.PTE has closed above bottom band by 33.8%. Bollinger Bands are 85.3% wider than normal. The large width of the bands suggest high volatility as compared to PTE's normal range. The bands have been in this wide range for 11 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 19 Feb 2021
What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition - Simply Wall St
Fri, 19 Feb 2021
What Percentage Of PolarityTE, Inc. (NASDAQ:PTE) Shares Do Insiders Own? - Yahoo Finance
Fri, 12 Feb 2021
Premarket Mover: Polarityte Inc (PTE) Up 4.49% - InvestorsObserver
Wed, 10 Feb 2021
Should Polarityte Inc (PTE) be in Your Portfolio? - InvestorsObserver
Wed, 10 Feb 2021
PolarityTE Provides Corporate Update - Business Wire
Tue, 09 Feb 2021
Premarket Mover: Polarityte Inc (PTE) Up 8.53% - InvestorsObserver
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
67 |
| Shares Float (M) |
29 |
|
% Held by Insiders
|
25.36 |
|
% Held by Institutions
|
16.64 |
|
Shares Short (K)
|
3,580 |
|
Shares Short P. Month (K)
|
1,380 |
Stock Financials |
|
EPS
|
-1.572 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.700 |
|
Profit Margin
|
|
|
Operating Margin
|
-654.81 |
|
Return on Assets (ttm)
|
-56.1 |
|
Return on Equity (ttm)
|
-140.2 |
|
Qtrly Rev. Growth
|
139.2 |
|
Gross Profit (p.s.)
|
0.047 |
|
Sales Per Share
|
0.120 |
|
EBITDA (p.s.)
|
-0.735 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-48 |
|
Levered Free Cash Flow (M)
|
-26 |
Stock Valuations |
|
PE Ratio
|
-0.87 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.96 |
|
Price to Sales
|
11.48 |
|
Price to Cash Flow
|
-1.91 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2016-01-14 |
|
Ex-Dividend Date
|
2016-01-11 |
|
7 Binary Options
|
|
Your Ad Here
|
|
